Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?

Abstract

On 7 June the FDA approved aducanumab, the first new drug for Alzheimer's disease in almost 20 years-and notably, the first drug with a putative disease-modifying mechanism for the treatment of this devastating disorder, namely the removal of β-amyloid (or Aβ) plaques from the brain.